What is Brukinsa (zanubrutinib) used for? 1 bottle with 120 capsules of 80 mg
- Mantle cell lymphoma (MCL) after at least one prior therapy
- Advanced marginal zone lymphoma (MZL) for people who didn’t respond well to other anticancer medications
- Waldenström macroglobulinemia (WM)
- Chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL)
- Advanced follicular lymphoma (FL)
| Usage/Application | Hospital | |
| Compostion | Zanubrutinib 80 mg | |
| Brand Name | Brukinsa 80 mg Capsule | |
| Usage |
| |
SIZE GUIDE
| SIZE | XS | S | M | L | XL | XXL |
|---|---|---|---|---|---|---|
| BUST | 88 | 89 | 90 | 91 | 92 | 93 |
| WAIST | 55 | 56 | 58 | 59 | 62 | 65 |
| HIPS | 90 | 92 | 94 | 95 | 96 | 98 |
| SIZE | XS | S | M | L | XL | XXL |
|---|---|---|---|---|---|---|
| BUST | 60 | 62 | 65 | 66 | 68 | 69 |
| WAIST | 50 | 55 | 58 | 62 | 65 | 66 |
| HIPS | 80 | 82 | 85 | 86 | 88 | 89 |
| Size | US | UK / AUS | France | Italy | Japan | Denmark |
|---|---|---|---|---|---|---|
| XS | 0-2 | 6 | 34 | 38 | 5 | 32 |
| S | 2-4 | 8 | 36 | 40 | 7 | 34 |
| M | 6-8 | 10 | 38 | 42 | 9 | 36 |
| L | 8-10 | 12 | 40 | 44 | 11 | 38 |
Description
Brukinsa (zanubrutinib) is a Bruton’s Tyrosine Kinase (BTK) inhibitor indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL), Waldenström’s Macroglobulinemia (WM), relapsed/refractory Marginal Zone Lymphoma (MZL).
Brukinsa (zanubrutinib) was approved by the FDA in November 2019 and by the EMA in November 2021.
Shipping
Room temperature shipping
For this medication, standard shipping applies. This means that a consistent room temperature of 15 to 25°C is maintained during transit.
BRUKINSA is an anticancer medicine that contains the active substance zanubrutinib. It belongs to a class of medicines called protein kinase inhibitors. This medicine works by blocking Bruton’s tyrosine kinase, a protein in the body that helps cancer cells grow and survive
How Brukinsa (zanubrutinib) works
There’s a pathway inside some cells called the Bruton tyrosine kinase pathway, that sends signals that tell cells to grow and divide. This pathway is particularly active in B-cell cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
Brukinsa (zanubrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor. It blocks a specific protein in the Bruton tyrosine kinase pathway so that the cancer cells can’t grow or spread as well.
Drug Facts
What are the side effects of Brukinsa (zanubrutinib)?
Common Side Effects
- Higher blood sugar levels (55%)
- Low blood cell counts, all (up to 50%)
- Muscle or joint pain (up to 45%)
- Cough, runny nose, and other symptoms of an upper respiratory tract infection (up to 44%)
- Bleeding (up to 42%)
- Rash (up to 36%)
- Higher creatinine levels (34%)
- Tiredness (up to 31%)
- Higher liver enzyme levels (up to 28%)
- Changes in electrolyte levels (up to 27%)
- Diarrhea (up to 25%)
- Higher potassium levels (24%)
- Bruising (up to 24%)
Other Side Effects
- Nausea
- Headache
- Fever
- Constipation
- Vomiting
- Itching
- Dizziness
- Swelling in the hands and feet
Note: These side effects were reported by people in clinical trials for MCL, MZL, or WM.
Serious Side Effects
- Serious infections: body aches, chills, fever, headache, new cough, sore throat, feeling tired, lowered blood cell counts
- Serious bleeding (general): bleeding or bruising that doesn’t stop or go away, large amount of bleeding, blood in the urine, throwing up blood, bloody or black and tarry stool
- Brain bleeds: headache, weakness, changes in vision, nausea, vomiting, trouble speaking or understanding speech, difficulty maintaining balance
- Stomach bleeds: dizziness, trouble breathing, feeling faint, stomach pain, nausea, vomiting, bright red blood in vomit, dark and tarry stool
- Heart rhythm problems: fainting, dizziness, chest pain, fast heartbeat, dizziness, difficulty breathing

















There are no reviews yet.